VASOPRESSIN IN SODIUM CHLORIDE 0.9% (vasopressin)
Vasopressin helps adults with vasodilatory shock by increasing their blood pressure. It is specifically used for patients who remain hypotensive even after being treated with fluids and catecholamines. This medication provides a critical intervention to stabilize blood pressure when standard initial treatments are not sufficient.
How VASOPRESSIN IN SODIUM CHLORIDE 0.9% Works
Vasopressin works by binding to V1 receptors on vascular smooth muscle, which triggers the release of intracellular calcium to cause blood vessels to constrict. Additionally, it stimulates V2 receptors to promote antidiuresis. These actions together help raise the patient's blood pressure.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2023-09-29
- Patent Cliff
- 2044
- Routes
- INTRAVENOUS
- Dosage Forms
- SOLUTION
VASOPRESSIN IN SODIUM CHLORIDE 0.9% Approval History
What VASOPRESSIN IN SODIUM CHLORIDE 0.9% Treats
2 indicationsVASOPRESSIN IN SODIUM CHLORIDE 0.9% is approved for 2 conditions since its original approval in 2023. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Vasodilatory Shock
- Hypotension
VASOPRESSIN IN SODIUM CHLORIDE 0.9% Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to VASOPRESSIN IN SODIUM CHLORIDE 0.9%
3 of 16FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
21 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT05958342 CAVALIER | STUDY23040043 W81XWH-6-D-0024 | Ph 2 | recruiting | CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial |
| NCT05738148 | Pro00122275 | Ph 1 | active not recruiting | Vasopressin vs. Epinephrine During Neonatal Cardiopulmonary Resuscitation |
| NCT02118467 | 14-0047 | Ph 4 | recruiting | Vasoactive Drugs in Intensive Care Unit |
| NCT05568160 NOVACC | GUINOT PHRCI 2019 | Ph 3 | active not recruiting | Evaluation of the Superiority of VAsopressin Versus NOradrenaline in the Management of Patients at Risk of Kidney Failure Undergoing Cardiac Surgery With Extracorporeal Circulation |
| NCT06217562 VASSPR | 1052518 | Ph 4 | active not recruiting | Vasopressin for Septic Shock Pragmatic Trial |
| NCT06547892 NOVA-AKI | NOVA-AKI | Ph 2 | recruiting | Use of Vasopressin in Patients at High Risk of Acute Kidney Injury Admitted to the ICU |
| NCT04501861 results posted | 20-301 | Ph 3 | completed | Hemodynamic Effect of Norepinephrine Versus Vasopressin on the Pulmonary Circulation in Cardiac Surgery Patients: |
| NCT06419075 TEXAS | 23-0273 | Ph 4 | withdrawn | Tranexamic Acid in Vaginal Reconstructive Surgery |
| NCT02975999 results posted | HRP-530 | Ph 2, Ph 3 | completed | Use of Vasopressin Following the Fontan Operation |
| NCT05193370 | 21-040 UL1TR001449 | Ph 4 | withdrawn | Angiotensin II vs. Vasopressin in Septic Shock |
| NCT03483753 VANCSIII | 62586316.6.0000.0065 | Ph 2, Ph 3 | withdrawn | Vasopressin or Norepinephrine in Vasoplegic Shock After Non-cardiac Surgery |
| NCT01093768 | 100068 10-M-0068 | Ph 1 | completed | Brain Imaging Study of Adults With Autism Spectrum Disorders |
| NCT00628550 Vasopressin | 082007-065 | Ph 1 | completed | Trial of Vasopressin and Epinephrine to Epinephrine Only for In-Hospital Pediatric Cardiopulmonary Resuscitation |
| NCT01962870 results posted | IRB-26034 R21MH100387-01 | Ph 2 | completed | The Role of Vasopressin in the Social Deficits of Autism |
| NCT01611935 AVERTShock results posted | 811293 | Ph 2 | completed | AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock |
| NCT03930069 | Hysterscopioc myomectomy | Ph 2, Ph 3 | completed | Vasopressin Injection Versus Misoprostol During Hysteroscopic Myomectomy In Reducing Blood Loss And Operation Time. |
| NCT01718613 VANCS II | NP 1079/17 | Ph 3 | completed | Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients |
| NCT01393704 results posted | 2011-P-000264/1 | Ph 4 | completed | Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial |
| NCT02454348 NOVEL | 204265 | Ph 4 | withdrawn | NOrepinephrine and VasoprEssin Versus Norepinephrine aLone in Critically Ill Patients With Septic Shock |
| NCT01861015 | KNC13-013 | Ph 3 | completed | Vasopressin Versus Epinephrine in Myomectomy |
| NCT00379522 | Vitris | Ph 2, Ph 3 | completed | Vasopressin in Traumatic Hemorrhagic Shock Study |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
VASOPRESSIN IN SODIUM CHLORIDE 0.9% FDA Label Details
Indications & Usage
FDA Label (PDF)VASOPRESSIN IN SODIUM CHLORIDE 0.9% is indicated for the treatment of Vasodilatory Shock; Hypotension.
VASOPRESSIN IN SODIUM CHLORIDE 0.9% Patents & Exclusivity
Patents (1 active)
Pro Intelligence Preview
Deep insights for VASOPRESSIN IN SODIUM CHLORIDE 0.9%
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2044
- • 4 active patents
Trial Analysis
- • 21 total trials
- • Stage: Stable
Competitive Landscape
- • 16 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment